# Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

> **NCT00457821** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 39 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ivacaftor 25 mg/75 mg
- **DRUG:** Ivacaftor 75 mg/150 mg
- **DRUG:** Ivacaftor 150 mg or 250 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00457821
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457821, "Safety Study of Ivacaftor in Subjects With Cystic Fibrosis". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT00457821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*